fbpx

Lipocine Inc

LPCN

$5.02

Closing

▼-4.56%

1D

▲81.88%

YTD

LPCN

BBG0029L1Y76

Exchange

Sector

Market cap

$28.77M

Volume

6,297

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$28.77M

Analysts' Rating

STRONG BUY

Price Target (Mean)

10.00

Total Analysts

2

P/E

Operating Margin

0.00%

Beta

1.26

Revenue Growth

100.00%

52 week high

$11.76

52 week low

$2.54

Div. Yield

%

EPS Growth

-28.07

Company Profile

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.